Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7337301

COc1ccc2ccc(C(=N)N)cc2c1OC.O=C(O)C(F)(F)F

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PLAU P00749 12/20 0.64
PRSS1 P07477 7/20 0.47
F2 P00734 4/20 0.47
PLG P00747 4/20 0.47
KLK1 P06870 3/20 0.47
PLAT P00750 2/20 0.47
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA7 P43166 1/20 0.41
TPMT P51580 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7337885 0.90 PLAU (0.55) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7345791 0.88 PLAU (0.84) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7339921 0.88 PLAU (0.57) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7333225 0.88 PLAU (0.73) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7592047 0.87 PLAU (0.56) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7456773 0.86 PLAU (0.70) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7335260 0.86 PLAU (0.53) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7339090 0.85 PLAU (0.57) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7344757 0.85 PLAU (0.62) PLAUPRSS1F2PLGKLK1
Trifluoroacetic Acid SCHEMBL7336904 0.83 PLAU (0.59) PLAUPRSS1F2PLGKLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885PRSS1 16/4885F2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.